Guillermo Arán Toha, Ana Collazos Blanco, Ana Belén Negredo, Alicia Inés García Señán, Ana Sarria Visa, Sara Medrano Pardo, Miriam Estébanez, German Ramíez-Olivencia, Francisco Javier Membrillo de Novales, Mónica Sánchez Martínez, Carolina Plaza Cristóbal, Laura Diana Guijarro Redondo, Octavio Alejandro Arce Garcia, Silvia Carballo Gobbo, Cinta Villaverde Caro, María Teresa Palacios Valhondo, Adrián Sancho de Andrés, Ana Isabel López Figueras, María Paz Sánchez Seco, María Simón Sacristán
{"title":"Andes virus molecular diagnosis and viral RNA kinetics using a research use only RT-PCR assay: Experience from a Spanish tertiary hospital.","authors":"Guillermo Arán Toha, Ana Collazos Blanco, Ana Belén Negredo, Alicia Inés García Señán, Ana Sarria Visa, Sara Medrano Pardo, Miriam Estébanez, German Ramíez-Olivencia, Francisco Javier Membrillo de Novales, Mónica Sánchez Martínez, Carolina Plaza Cristóbal, Laura Diana Guijarro Redondo, Octavio Alejandro Arce Garcia, Silvia Carballo Gobbo, Cinta Villaverde Caro, María Teresa Palacios Valhondo, Adrián Sancho de Andrés, Ana Isabel López Figueras, María Paz Sánchez Seco, María Simón Sacristán","doi":"10.1016/j.jcv.2026.106019","DOIUrl":"https://doi.org/10.1016/j.jcv.2026.106019","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the clinical performance and qualitative agreement of a commercially available Research Use Only (RUO) real-time RT-PCR assay for Andes virus (ANDV) detection and longitudinal molecular monitoring during the first imported ANDV outbreak managed in Spain.</p><p><strong>Methods: </strong>Fourteen repatriated individuals exposed to an ANDV outbreak underwent molecular screening using whole blood and serum specimens. Confirmed cases were prospectively monitored with serial whole blood, serum, oropharyngeal swab, urine, and rectal swab specimens collected every 72 h. Clinical specimens were inactivated in a Biosafety Level 3 facility before automated RNA extraction and testing with the RealStar® Hantavirus-HPS RT-PCR assay (Altona Diagnostics, Hamburg, Germany). All specimens were also analyzed at the Spanish National Reference Laboratory using a hantavirus-specific real-time RT-PCR reference method. Qualitative agreement, Ct value correlation, and viral RNA kinetics were assessed.</p><p><strong>Results: </strong>A total of 185 clinical specimens were analyzed, including 124 screening specimens from exposed individuals and 61 specimens collected during longitudinal follow-up of two confirmed cases. All 124 screening specimens were negative by both assays (124/124, 100% agreement). Among follow-up specimens, overall qualitative agreement was 93.4% (57/61; κ=0.837), and Ct values showed a strong correlation between assays (Pearson's r = 0.965). Four discordant results occurred in specimens with high Ct values (≥34-35), consistent with low concentrations of detectable viral RNA. Whole blood showed the lowest Ct values and the longest persistence of detectable viral RNA among the specimen types evaluated.</p><p><strong>Conclusions: </strong>The RealStar® Hantavirus-HPS RT-PCR assay showed high qualitative agreement with the reference method in the clinical specimens evaluated and provided timely molecular information during outbreak investigation and longitudinal follow-up. Whole blood may be useful for longitudinal detection of ANDV RNA; however, these findings are descriptive and do not establish generalized viral shedding kinetics or infectivity. Further analytical and clinical studies are required to establish the assay's performance and clinical utility.</p>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"187 ","pages":"106019"},"PeriodicalIF":3.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kajal M. Patel, Erika A. Roloff, Paa K. Annobil, Pushker Raj
{"title":"Corrigendum to “A laboratory-developed test for the automated molecular detection of mpox clade I, mpox clade II, and non-variola Orthopoxvirus using the Panther Fusion® System” [J. Clin. Virol., 181 (2025) 105887]","authors":"Kajal M. Patel, Erika A. Roloff, Paa K. Annobil, Pushker Raj","doi":"10.1016/j.jcv.2026.105976","DOIUrl":"10.1016/j.jcv.2026.105976","url":null,"abstract":"","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"185 ","pages":"Article 105976"},"PeriodicalIF":3.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaoqin Yuan , Xinyi Xiang , Hongqian Xu , Wencen Lu , JinJing Zhang , Zhili Hu , Shiying Li , Li Zhou
{"title":"A machine learning model for predicting complete virological response in chronic hepatitis B patients receiving first-line nucleos(t)ide analogues therapy","authors":"Xiaoqin Yuan , Xinyi Xiang , Hongqian Xu , Wencen Lu , JinJing Zhang , Zhili Hu , Shiying Li , Li Zhou","doi":"10.1016/j.jcv.2026.105921","DOIUrl":"10.1016/j.jcv.2026.105921","url":null,"abstract":"<div><h3>Background</h3><div>Complete virological response (CVR) is the primary goal of nucleos(t)ide analogues (NAs) therapy for chronic hepatitis B (CHB) patients. The objective of this study was to develop and validate a machine learning (ML) model to predict CVR in CHB patients receiving first-line NAs.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 2394 CHB patients treated with first-line NAs, randomly divided into a training set and an internal validation set at a 7:3 ratio. Key predictors were identified through univariate analysis, followed by Lasso, SVM-RFE, and Boruta feature selection algorithms. Seven machine learning models were developed and compared, interpreting results with SHapley Additive exPlanations (SHAP) analysis.</div></div><div><h3>Results</h3><div>A total of 2394 CHB patients were included, among whom 1597 (66.7 %) achieved CVR. Baseline HBV DNA, HBeAg, DBIL, Age, Cirrhosis, ALT, PLT, FIB4, and HBsAg were identified as significant influencing factors. Among the seven ML methods, the XGBoost model demonstrated the best performance with an AUC of 0.864 in the training set and 0.823 in the validation set. SHAP analysis identified baseline HBV DNA and HBeAg status as the top two predictors. This web-based calculator is designed to help predict the probability of achieving CVR at 48 weeks in CHB patients receiving first-line NAs treatment (<span><span>http://yuanxq.shinyapps.io/CVR-prediction-app</span><svg><path></path></svg></span>).</div></div><div><h3>Conclusion</h3><div>We developed and validated an interpretable machine learning model to predict CVR at 48 weeks in CHB patients treated with first-line NAs.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"183 ","pages":"Article 105921"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Susanne Pfefferle, Dominik Nörz, Katja Giersch, Moritz Grunwald, Hui Ting Tang, Lisa Sophie Pflüger, Marc Lütgehetmann
{"title":"Refined fully automated RT-qPCR assay for simultaneous detection of SARS-CoV-2, Influenza A/B, and RSV with target optimization for improved variant resilience","authors":"Susanne Pfefferle, Dominik Nörz, Katja Giersch, Moritz Grunwald, Hui Ting Tang, Lisa Sophie Pflüger, Marc Lütgehetmann","doi":"10.1016/j.jcv.2026.105924","DOIUrl":"10.1016/j.jcv.2026.105924","url":null,"abstract":"<div><h3>Background</h3><div>Continuous viral evolution is likely to cause a loss of performance or failure of existing diagnostic assays. Here, we delineate the adaptation and validation of an operational laboratory developed (LDT) multiplex RT-qPCR for simultaneous detection of SARS-CoV-2, influenza A/B (FluA/B) and respiratory syncytial virus (RSV) on a high-throughput, fully automated platform. Furthermore, we explore the integration of an alternative SARS-CoV-2 target to enhance assay robustness</div></div><div><h3>Methods</h3><div>An adaption of the operational assay (PMID:38820916) was performed and a novel SARS-CoV-2 target (macrodomain, Mac1) was implemented. Analytical performance of the adapted assay was evaluated using digital-PCR based standards or international reference material and clinical performance was assessed on clinical samples with a CE-IVD comparator assay.</div></div><div><h3>Results</h3><div>Analytical sensitivity (lower limit of detection (LoD)) was 70.9 IU/ml for SARS-CoV-2, and 112–474, 919 and 1720 cp/ml for influenza A, influenza B and RSV, respectively, with linear ranges of 26.3–36.4 ct (SARS-CoV-2), 26.8–37.7 ct (FluA), 28.5–37.9 (FluB) and 25.6–38.2 (RSV). Clinical performance evaluation confirmed improved performance (e.g. FluA/B detection −1.6/-4.81 ct) and comparable performance to the CE-IVD assay (excellent correlation of the SARS-CoV-2 assays, more effective detection of influenza B). Overall, positive/negative agreement was 100 %/93 % (SARS-CoV-2), and 100 %/100 % (FluA/B, RSV).</div></div><div><h3>Conclusion</h3><div>The adapted LDT assay as a focused syndromic assay provides reliable detection of major respiratory viruses on a high-throughput platform. The strategic targeting of conserved genomic regions ensures diagnostic resilience, while automated integration facilitates scalable laboratory operations. This approach facilitates robust pathogen surveillance and expedites clinical decision-making during periods of co-circulation and epidemic surge.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"183 ","pages":"Article 105924"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Huanyu Wang , Kathy Everhart , Sophonie J. Oyeniran , Amy L. Leber
{"title":"Detection of La Crosse virus RNA in clinical specimens obtained from children with La Crosse infection","authors":"Huanyu Wang , Kathy Everhart , Sophonie J. Oyeniran , Amy L. Leber","doi":"10.1016/j.jcv.2026.105923","DOIUrl":"10.1016/j.jcv.2026.105923","url":null,"abstract":"<div><h3>Background</h3><div>La Crosse virus (LACV), a member of family <em>Peribunyaviridae</em>, genus <em>Orthobunyavirus</em>, is the leading cause of neuroinvasive arboviral infection in children in the United States. Diagnosis relies on detecting specific antibodies (IgG or IgM), a 4-fold titer rise or seroconversion, in patients with compatible presentations. NAAT used for LACV detection has largely been limited to mosquito, animal models or postmortem brain tissue. There is a lack of data on the performance of NAATs in clinical specimens from living patients.</div></div><div><h3>Methods</h3><div>Children who had positive arbovirus serology tests and a diagnosis of LACV encephalitis were identified. Remnant specimens including plasma, serum, CSF, throat swab (THT) or nasopharyngeal sample (NP) submitted to the laboratory for other diagnostic testing were retrieved and tested with LACV-PCR. Medical records were reviewed for demographics, presenting symptoms and test results.</div></div><div><h3>Results</h3><div>From June 2015 to October 2021, 61 patients had remnant specimens available for LACV-PCR and were included in this study. A total of 179 clinical specimens from these patients were tested, including 64 sera, 31 plasma, 33 CSF, 23 THT and 28 NP. Ten (5.3 %) samples collected from 8 (13.1 %) unique patients were positive for LACV RNA. The positive rates were 3.2 %, 0, 6.5 %, 3.5 % and 21.7 % for sera, plasma, CSF, NP and THT respectively.</div></div><div><h3>Conclusion</h3><div>There is limited utility of NAATs for diagnosis of LACV infection. NAATs may be useful in cases with delayed seroconversion or in immunocompromised individuals.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"183 ","pages":"Article 105923"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146070914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Practical management of positive norovirus results from FilmArray® GI panel","authors":"Noémie Rybak , Philippe Bidet , Yasmine Benhadid-Brahmi , Aurélie Cointe , Hosam Dawoud , Maud Gits-Muselli , Audrey Baron , Stéphane Bonacorsi , André Birgy","doi":"10.1016/j.jcv.2026.105922","DOIUrl":"10.1016/j.jcv.2026.105922","url":null,"abstract":"<div><h3>Background</h3><div>On February the 7th 2024, BioFire® alerted users to a risk of false-positive norovirus results with the BioFire® FilmArray® Gastrointestinal Panel (BF-GIP) and recommended confirmatory testing.</div></div><div><h3>Objectives</h3><div>To assess the reliability of BF-GIP norovirus-positive results in children and develop a decision algorithm for managing potential false positives.</div></div><div><h3>Study design</h3><div>Between January and June 2025, all BF-GIP norovirus-positive samples were re-tested the same day using the GeneXpert® Norovirus assay (Cepheid®). BF-GIP cycle thresholds (Ct) values and melting curves were analyzed.</div></div><div><h3>Results</h3><div>Of the 1007 BF-GIP performed, 131 were norovirus-positive and 127 were retested by the GeneXpert® Norovirus assay. Overall, 31.5 % (40/127) were discordant. Atypical melting curves (22/40, 55 %), high Ct values (> 25) or “N/A” results were strongly associated with discordance, while Ct ≤ 20 were highly predictive of concordance. Based on these metrics, 58 % of BF-GIP norovirus-positive results could be confidently confirmed or rejected without additional testing.</div></div><div><h3>Conclusion</h3><div>False norovirus-positive results by the BF-GIP are common. An algorithm integrating BF-GIP Ct values and melting curve analysis can reduce unnecessary retesting, streamline laboratory workflow and support accurate diagnosis in pediatric settings.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"183 ","pages":"Article 105922"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146076849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana I. Cubas Atienzar , Christopher T. Williams , Yasemin Cosgun , Fatma Gonca Arslan , Hakan Hedef , Ilkay Bozkurt , Kevin S. Richards , Sian Summers , James Pitman , Shaun Ainsworth , Gino Miele , Cristina Leggio , William Nicholas , Hilary Bower , Benedict Gannon , Tom E. Fletcher , Gulay Korukluoglu , Thomas Edwards
{"title":"Development and evaluation of a novel RT-qPCR assay for detection of Crimean Congo haemorrhagic fever virus using the Genedrive® point-of-care platform","authors":"Ana I. Cubas Atienzar , Christopher T. Williams , Yasemin Cosgun , Fatma Gonca Arslan , Hakan Hedef , Ilkay Bozkurt , Kevin S. Richards , Sian Summers , James Pitman , Shaun Ainsworth , Gino Miele , Cristina Leggio , William Nicholas , Hilary Bower , Benedict Gannon , Tom E. Fletcher , Gulay Korukluoglu , Thomas Edwards","doi":"10.1016/j.jcv.2025.105889","DOIUrl":"10.1016/j.jcv.2025.105889","url":null,"abstract":"<div><h3>Introduction</h3><div>Crimean-Congo haemorrhagic fever (CCHF) is a viral haemorrhagic fever classed by the World Health Organization as a priority disease due to the lack of countermeasures. A point-of-care (POC) diagnostic test for rapid detection of positive cases to expedite patient management is not currently available but urgently needed.</div></div><div><h3>Methods</h3><div>We have developed an RT-qPCR assay to be used with the commercially available POC Genedrive® PCR platform enabling viral detection in serum with minimal sample preparation. The sensitivity and specificity of the novel assay in the Genedrive® was evaluated against the RealStar® CCHFV RT-qPCR Kit (Altona Diagnostics, Germany).</div></div><div><h3>Results</h3><div>The sensitivity and specificity in assay V1 (sample n = 150) were 94.4 % (95 % CI, 88.2–97.9) and 97.6 % (95 % CI, 87.1–99.9). For assay (n = 55) V2 sensitivity was 92.3 % (95 % CI, 74.9–99.5) and specificity was 100 % (95 % CI, 87.7–100).</div></div><div><h3>Conclusions</h3><div>This study supports the feasibility of diagnosing CCHF using POC RT-qPCR platforms, having the potential to reduce turnaround times, leading to improved clinical management.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"182 ","pages":"Article 105889"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eduardo L. López , Fausto Martín Ferolla , Agustina F. Denardi , Noelia Iraizos , Ana Fernández , María M. Contrini , Patricio L. Acosta
{"title":"Bacterial colonization and life-threatening respiratory syncytial virus infection in children","authors":"Eduardo L. López , Fausto Martín Ferolla , Agustina F. Denardi , Noelia Iraizos , Ana Fernández , María M. Contrini , Patricio L. Acosta","doi":"10.1016/j.jcv.2025.105891","DOIUrl":"10.1016/j.jcv.2025.105891","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus is a major cause of acute respiratory infection in children. While most cases are mild, some progress to life-threatening disease. The role of bacterial colonization in shaping respiratory syncytial virus outcomes remains incompletely understood.</div></div><div><h3>Objective</h3><div>To evaluate the association between respiratory tract bacterial colonization and respiratory syncytial virus disease severity in children.</div></div><div><h3>Study design</h3><div>Prospective cohort study conducted during 2019 and 2023. Children ≤ 24 months hospitalized with confirmed positive respiratory syncytial virus infection were enrolled. Clinical and epidemiological data were collected. respiratory syncytial virus subtypes, viral load, and detection of <em>Haemophilus influenzae</em>, <em>Streptococcus pneumoniae</em>, and <em>Moraxella catarrhalis</em> were determined by qPCR.</div></div><div><h3>Results</h3><div>401 patients were hospitalized with acute respiratory infection, of which 172 (42.9 %) had confirmed respiratory syncytial virus infection. Among them, 15 (8.7 %) developed life-threatening disease. Bacterial colonization was highly prevalent (92.4 %): <em>H. influenzae</em> (68 %), <em>S. pneumoniae</em> (64.5 %), and <em>M. catarrhalis</em> (52.9 %). <em>M. catarrhalis</em> colonization was associated with mild disease (p = 0.003), while <em>H. influenzae</em> showed a trend toward increased severity (p = 0.054). Viral subtype and viral load were not linked to severity. Household crowding was independently associated with more severe disease (p = 0.031).</div></div><div><h3>Conclusions</h3><div>Our results support the growing evidence that airway microbiota modulates respiratory syncytial virus outcomes and highlights <em>M. catarrhalis</em> as potential microbial determinant of disease progression.</div></div>","PeriodicalId":15517,"journal":{"name":"Journal of Clinical Virology","volume":"182 ","pages":"Article 105891"},"PeriodicalIF":3.4,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}